Normunity
3 known investors
Normunity develops novel anti-cancer therapies that target interactions between the immune system and tumors to improve drug efficacy and immune response. The company leverages a research partnership with Yale School of Medicine to identify new therapeutic targets in biologic medicine for solid tumors.
Biotech
Investors · 3
In the news
- Normunity raises $75m to advance solid tumour targeting T-cell engagers - Pharmaceutical Technologypharmaceutical-technology.com · 2025
- Normunity: $75 Million (Series B) Raised For Broadening Pipeline Of Novel Anti-Cancer Therapiespulse2.com · 2025
- Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanismsbusinesswire.com · 2025
- Normunity - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2022
- Normunity Raises $65M in Series A Financingfinsmes.com · 2022
- About Us - Normunitynormunity.com · 2022